Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | HINT1 | P49773 | 6/20 | 0.61 |
| ▸ | GSK3A | P49840 | 2/20 | 0.56 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
| ▸ | PNP | P00491 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.51 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.51 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.51 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4386265 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL3422978 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL278167 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL1120690 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL1061031 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL25407962 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL13462039 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL14144174 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL13296251 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL16809000 | 0.95 | ALDH1A1 (0.63) | ALDH1A1LMNATP53MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190225644-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | MODERNATX, INC. | 2019-07-25 | — | — | US | disclosed |
| US-20190211368-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | MODERNATX, INC. | 2019-07-11 | — | — | US | disclosed |
| WO-2017066782-A1 | HYDROPHOBIC MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20120195827-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | GILEAD SCIENCE, INC. | 2012-08-02 | — | — | US | disclosed |
| US-8183226-B2 | Myocardial perfusion imaging method | GILEAD SCIENCES, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8133879-B2 | Myocardial perfusion imaging methods and compositions | GILEAD SCIENCES, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110144320-A1 | N-PYRAZOLE A2A RECEPTOR AGONISTS | GILEAD PALO ALTO, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20100272645-A1 | MYOCARDIAL PERFUSION IMAGING METHOD | GILEAD PALO ALTO, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100183503-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | GILEAD PALO ALTO, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100160620-A1 | N-PYRAZOLE A2A RECEPTOR AGONISTS | GILEAD PALO ALTO, INC. | 2010-06-24 | — | — | US | disclosed |
| US-7683037-B2 | A2A receptor agonist; regadenoson (CVT-3146); produces coronary vasodilation without significant peripheral vasodilation; | GILEAD PALO ALTO, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7655637-B2 | N-pyrazole A2A receptor agonists | GILEAD PALO ALTO, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655637-B2 | N-pyrazole A2A receptor agonists | GILEAD PALO ALTO, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-7553823-B2 | C-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090081120-A1 | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods | CV THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20080213165-A1 | Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods | CV THERAPEUTICS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20070203090-A1 | N-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20060052332-A1 | N-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2006-03-09 | — | — | US | disclosed |
| US-20040038928-A1 | N-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2004-02-26 | — | — | US | disclosed |
| US-6642210-B1 | Administering compound to mammal by intravenous bolus injection to stress heart and induce coronary steal situation, stimulating coronary vasodilation, in order to image heart | CV THERAPEUTICS, INC. | 2003-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038928-A1 | N-pyrazole A2A receptor agonists | ADORA2A, ADORA3, ADORA1 | ALDH1A1 1118/4885LMNA 3308/4885TP53 4170/4885 |
| US-20100183503-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | ADORA2A, ADORA3, ADORA1 | ALDH1A1 1336/4885LMNA 1298/4885TP53 2068/4885 |
| US-20100272645-A1 | MYOCARDIAL PERFUSION IMAGING METHOD | ADORA2A, ADORA3, ADORA2B | ALDH1A1 1258/4885LMNA 2390/4885TP53 4038/4885 |
| US-20190211368-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | RNGTT, RNMT, CPSF7 | ALDH1A1 4506/4885LMNA 2216/4885TP53 990/4885 |
| US-20060052332-A1 | N-pyrazole A2A receptor agonists | ADORA2A, ADORA3, TBXA2R | ALDH1A1 1264/4885LMNA 3247/4885TP53 4204/4885 |
| US-20110144320-A1 | N-PYRAZOLE A2A RECEPTOR AGONISTS | ADORA2A, ADORA3, TBXA2R | ALDH1A1 1264/4885LMNA 3247/4885TP53 4204/4885 |
| US-20080213165-A1 | Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods | ADORA2A, ADORA3, ADORA1 | ALDH1A1 1130/4885LMNA 1087/4885TP53 4421/4885 |
| US-20100160620-A1 | N-PYRAZOLE A2A RECEPTOR AGONISTS | ADORA2A, ADORA3, TBXA2R | ALDH1A1 1264/4885LMNA 3247/4885TP53 4204/4885 |
| US-20090081120-A1 | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods | ADORA2A, FABP3, ADORA3 | ALDH1A1 1118/4885LMNA 785/4885TP53 4592/4885 |
| US-20120195827-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | ADORA2A, ADORA3, ADORA1 | ALDH1A1 1336/4885LMNA 1298/4885TP53 2068/4885 |
| US-20190225644-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | RNGTT, RNMT, NSUN2 | ALDH1A1 3967/4885LMNA 2009/4885TP53 1714/4885 |
| US-20070203090-A1 | N-pyrazole A2A receptor agonists | ADORA2A, ADORA3, TBXA2R | ALDH1A1 1264/4885LMNA 3247/4885TP53 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.